{"id":"https://openalex.org/W2591424065","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.8016","title":"Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study.","display_name":"Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study.","publication_year":2010,"publication_date":"2010-05-20","ids":{"openalex":"https://openalex.org/W2591424065","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.8016","mag":"2591424065"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2010.28.15_suppl.8016","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.8016","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.8016","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5032464400","display_name":"Kenneth Carl Anderson","orcid":"https://orcid.org/0000-0002-6418-0886","observed_orcids":["https://orcid.org/0000-0002-6418-0886"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. C. Anderson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000527476","display_name":"Edie A. Weller","orcid":"https://orcid.org/0000-0003-3845-7711","observed_orcids":["https://orcid.org/0000-0003-3845-7711"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. Weller","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023276777","display_name":"Sagar Lonial","orcid":"https://orcid.org/0000-0002-8322-9323","observed_orcids":["https://orcid.org/0000-0002-8322-9323"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Lonial","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103070449","display_name":"Andrzej J. Jakubowiak","orcid":"https://orcid.org/0000-0002-4550-4726","observed_orcids":["https://orcid.org/0000-0002-4550-4726"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. J. Jakubowiak","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028046297","display_name":"Sundar Jagannath","orcid":"https://orcid.org/0000-0003-2934-6518","observed_orcids":["https://orcid.org/0000-0003-2934-6518"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Jagannath","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069645152","display_name":"N. S. Raje","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N. S. Raje","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052641327","display_name":"David Avigan","orcid":"https://orcid.org/0000-0003-4624-6017","observed_orcids":["https://orcid.org/0000-0003-4624-6017"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Avigan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050333678","display_name":"Robert Knight","orcid":"https://orcid.org/0000-0001-9920-836X","observed_orcids":["https://orcid.org/0000-0001-9920-836X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. D. Knight","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110217259","display_name":"Dixie L. Esseltine","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Esseltine","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5043526996","display_name":"Paul Gerard Guy Richardson","orcid":"https://orcid.org/0000-0002-7426-8865","observed_orcids":["https://orcid.org/0000-0002-7426-8865"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. G. Richardson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"15_suppl","first_page":"8016","last_page":"8016"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.8799999952316284},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":1.0},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":1.0},{"id":"https://openalex.org/keywords/newly-diagnosed-multiple-myeloma","display_name":"newly diagnosed multiple myeloma","score":0.9210000038146973},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8059999942779541},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7720000147819519},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9110000133514404},{"id":"https://openalex.org/keywords/sensory-neuropathy","display_name":"sensory neuropathy","score":0.8889999985694885},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.48100000619888306},{"id":"https://openalex.org/keywords/autologous-stem-cell-transplantation","display_name":"autologous stem cell transplantation","score":0.9629999995231628},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.5360000133514404},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6370000243186951},{"id":"https://openalex.org/keywords/response-rate","display_name":"response rate","score":0.46000000834465027},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.550000011920929},{"id":"https://openalex.org/keywords/prognostic-score","display_name":"prognostic score","score":0.382999986410141}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8877305388450623},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.8225963115692139},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.657820999622345},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5891472101211548},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.5872486233711243},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5859091281890869},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5580854415893555},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.507860004901886},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.4915700852870941},{"id":"https://openalex.org/C2779609412","wikidata":"https://www.wikidata.org/wiki/Q203174","display_name":"Thalidomide","level":3,"score":0.45892930030822754},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.34815260767936707},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.3031301498413086}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2010.28.15_suppl.8016","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.8016","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.8016","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2555603866","https://openalex.org/W2283915390","https://openalex.org/W2564026069","https://openalex.org/W2549511714","https://openalex.org/W2554032537","https://openalex.org/W4250653753","https://openalex.org/W2590460846","https://openalex.org/W2248890568","https://openalex.org/W2564114766","https://openalex.org/W1969648097"],"abstract_inverted_index":{"8016":[0],"Background:":[1],"Bortezomib":[2],"(VELCADE,":[3],"Bz)":[4],"or":[5,65,97,326,332,357,361],"lenalidomide":[6],"(REVLIMID,":[7],"Len)":[8],"plus":[9],"dexamethasone":[10],"(dex)":[11],"demonstrate":[12],"substantial":[13],"activity":[14],"in":[15,24,38,119,313],"front-line":[16,39],"MM;":[17,136,142],"the":[18,25,30,35,84],"three-drug":[19,36],"combination":[20],"has":[21],"shown":[22],"efficacy":[23],"relapsed":[26],"setting.":[27],"This":[28],"was":[29,124,190,235,239,299],"first":[31],"prospective":[32],"study":[33],"of":[34,48,146,158,163,169,260,283],"regimen":[37],"MM.":[40],"Methods:":[41],"Patients":[42],"(pts)":[43],"received":[44,100,155],"eight":[45,251],"3-wk":[46],"cycles":[47,168],"Bz":[49,191],"1.0\u20131.3":[50],"mg/m2":[51],"(d":[52,60,68],"1,":[53,69],"4,":[54,71],"8,":[55,73,164],"11),":[56],"Len":[57,194],"15\u201325":[58],"mg":[59,67],"1\u201314),":[61],"and":[62,83,103,110,152,166,172,210,217,231,266,279,285,309,328],"dex":[63,197],"40":[64],"20":[66,198],"2,":[70],"5,":[72],"9,":[74],"11,":[75],"12)":[76],"at":[77],"5":[78],"dose":[79,87],"levels":[80],"(phase":[81],"I)":[82],"maximum":[85],"tolerated/planned":[86],"(MTD;":[88],"phase":[89,120],"II).":[90,121],"Responding":[91],"pts":[92,115,176,244,252,272],"could":[93],"receive":[94],"maintenance":[95],"therapy":[96],"ASCT.":[98,256,334],"Pts":[99,154],"prophylactic":[101],"anticoagulants":[102],"anti-viral":[104],"therapy.":[105],"Primary":[106],"endpoints":[107],"were":[108,116,129,204,277],"MTD":[109],"response":[111,284,325],"rate.":[112],"Results:":[113],"66":[114],"treated":[117],"(35":[118],"Median":[122],"age":[123],"58":[125],"(range":[126],"22\u201386);":[127],"55%":[128],"men;":[130],"44%/47%/9%":[131],"had":[132,138,144,177],"ISS":[133],"stage":[134],"I/II/III":[135],"68%/23%/9%":[137],"IgG/IgA":[139],"/light":[140],"chain":[141],"57%":[143],"any":[145],"del":[147,149],"13q,":[148],"17p,":[150],"t(4;14),":[151],"t(11;14).":[153],"a":[156,294],"median":[157,258],"10":[159],"cycles,":[160],"including":[161],"medians":[162],"10,":[165],"8":[167],"Bz,":[170],"Len,":[171],"dex,":[173],"respectively.":[174,221,281],"Two":[175],"dex-related":[178],"DLT":[179],"(grade":[180],"3":[181,184],"hyperglycemia,":[182],"grade":[183,219,223],"ALT":[185],"elevation).":[186],"Phase":[187,342],"II":[188,343],"dosing":[189],"1.3":[192],"mg/m2,":[193],"25":[195],"mg,":[196],"mg.":[199],"The":[200],"most":[201],"common":[202],"toxicities":[203,225],"sensory":[205],"neuropathy":[206],"(80%),":[207],"fatigue":[208],"(64%),":[209],"constipation":[211],"(61%),":[212],"with":[213,317,331],"only":[214],"2%,":[215],"3%,":[216],"0%":[218],"3,":[220],"Other":[222,371],"3/4":[224],"included":[226],"lymphopenia":[227],"(14%),":[228],"neutropenia":[229],"(9%),":[230],"thrombocytopenia":[232],"(6%).":[233,237],"Thrombosis":[234],"rare":[236],"There":[238],"no":[240,318],"treatment-related":[241],"mortality.":[242],"All":[243,340],"achieved":[245],"\u2265PR":[246,351],"to":[247,255,338],"Len-Bz-dex":[248,274,305,339],"(Table).":[249],"Twenty-":[250],"(42%)":[253],"proceeded":[254],"With":[257],"follow-up":[259],"21":[261],"months,":[262],"estimated":[263],"18-month":[264],"PFS":[265,286,298],"overall":[267],"survival":[268],"rates":[269],"among":[270],"all":[271],"after":[273],"with/without":[275],"ASCT":[276],"75%":[278],"97%,":[280],"Quality/rate":[282],"appeared":[287],"unaffected":[288],"by":[289],"adverse":[290,322],"cytogenetic":[291],"abnormalities.":[292],"In":[293],"1-yr":[295],"landmark":[296],"analysis,":[297],"similar":[300,329],"between":[301],"ASCT/non-ASCT":[302],"pts.":[303],"Conclusions:":[304],"demonstrates":[306],"favorable":[307],"tolerability":[308],"is":[310],"highly":[311],"effective":[312],"newly":[314],"diagnosed":[315],"MM,":[316],"impact":[319],"seen":[320],"from":[321],"cytogenetics":[323],"on":[324],"PFS,":[327],"outcomes":[330],"without":[333],"Best":[335],"responses":[336],"(%)":[337],"(N=66)":[341],"(N=35)":[344],"CR/nCR":[345],"39":[346],"57":[347],"\u2265VGPR":[348],"67":[349],"74":[350],"100":[352,353],"Author":[354],"Disclosure":[355],"Employment":[356],"Leadership":[358],"Position":[359],"Consultant":[360],"Advisory":[362],"Role":[363],"Stock":[364],"Ownership":[365],"Honoraria":[366],"Research":[367],"Funding":[368],"Expert":[369],"Testimony":[370],"Remuneration":[372],"Celgene,":[373,381,394,401,411],"Dana-Farber":[374],"Cancer":[375],"Institute,":[376],"Millennium":[377,398],"Amgen,":[378],"Bristol-Myers":[379,399,409],"Squibb,":[380,400,410],"Centocor":[382,402],"Ortho":[383,403],"Biotech,":[384,387,404,413],"Exelixis,":[385,405],"Facet":[386,412],"Johnson":[388,395],"&":[389,396],"Johnson,":[390,397],"Merck,":[391],"Millennium,":[392,406,415],"Novartis":[393,407,416],"AstraZeneca,":[408],"Glouchester,":[414]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2017-03-03T00:00:00"}